Literature DB >> 2496917

Role of tumor necrosis factor and interleukin 1 in gamma-interferon-promoted activation of mouse tumoricidal macrophages.

K Hori1, E Mihich, M J Ehrke.   

Abstract

The purpose of this study was to determine if recombinant murine interleukin 1 beta (rMu-IL-1 beta) alone or in combination with recombinant murine gamma-interferon (rMu-IFN-gamma) could activate murine macrophages to be tumoricidal against tumor necrosis factor (TNF)-insensitive target cells and to evaluate the possible role of interleukin 1 (IL-1) in murine macrophage activation by recombinant murine tumor necrosis factor (rMu-TNF) plus rMu-IFN-gamma. rMu-IL-1 beta and rMu-TNF alone or in combination could neither directly lyse the TNF-insensitive P815 mastocytoma nor activate resident peritoneal macrophages to be tumoricidal for this target. A synergistic induction of tumoricidal macrophage activity against P815 occurred, however, when either of these monokines was combined with rMu-IFN-gamma. The tumoricidal activity obtained was transitory, and the level of activity was dependent upon the monokine concentration and the length of induction period. Murine macrophages stimulated under the same conditions used to induce tumoricidal activity with rMu-TNF plus rMu-IFN-gamma or with rMu-IL-1 plus rMu-IFN-gamma were shown to produce low concentrations of IL-1 or TNF, respectively. Thus, a bidirectional cross-induction of the production of the two monokines occurred. The monokine production was also quite transitory, and the time of peak production of the monokines (12 h) was found to precede the time of peak tumoricidal activation (24 h). Using neutralizing antisera specific for rMu-IL-1s and rMu-TNF, the cross-induced production of TNF was shown to be required for macrophage tumoricidal activation by rMu-IL-1 beta alone (TNF-sensitive targets) or in combination with rMu-IFN-gamma (TNF-insensitive targets). There was no evidence, however, that the production of IL-1 was required for macrophage activation by rMu-TNF in combination with rMu-IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2496917

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Tumoricidal activation of murine resident peritoneal macrophages on pancreaticcarcinoma by interleukin-2 and monoclonal antibodies.

Authors:  Qi-Kui Chen; Shi-Zhen Yuan; Zhi-Yong Zeng; Zhi-Qing Huang
Journal:  World J Gastroenterol       Date:  2000-04       Impact factor: 5.742

2.  Differential effects of human blood monocytes on the growth of human tumour cell lines in vitro.

Authors:  H J Parry; R C Rees
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Tumor necrosis factor alpha rapidly activates the mitogen-activated protein kinase (MAPK) cascade in a MAPK kinase kinase-dependent, c-Raf-1-independent fashion in mouse macrophages.

Authors:  B W Winston; C A Lange-Carter; A M Gardner; G L Johnson; D W Riches
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

4.  Tumor necrosis factor in benign and malign tissue of the kidney.

Authors:  K H Bichler; S Kleinknecht; H J Nelde; W L Strohmaier
Journal:  Urol Res       Date:  1991

5.  Functional switching of macrophage responses to tumor necrosis factor-alpha (TNF alpha) by interferons. Implications for the pleiotropic activities of TNF alpha.

Authors:  F R Lake; P W Noble; P M Henson; D W Riches
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

6.  Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells.

Authors:  Ole Audun Werner Haabeth; Kristina Berg Lorvik; Hideo Yagita; Bjarne Bogen; Alexandre Corthay
Journal:  Oncoimmunology       Date:  2015-07-25       Impact factor: 8.110

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.